SCHEMBL4149172

SCHEMBL4149172

O=C1CCCCN1c1ccc(N2CCC[C@H](NC(=O)N3C4CCC3CC(O)C4)C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
RAB9A P51151 3/20 0.46
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.44
AKR1C3 P42330 2/20 0.41
LCK P06239 1/20 0.41
JAK3 P52333 1/20 0.41
KMT2A Q03164 1/20 0.41
FPR1 P21462 1/20 0.39
FPR2 P25090 1/20 0.39
GFER P55789 1/20 0.39
ALDH1A1 P00352 2/20 0.38
F10 P00742 2/20 0.38
F2 P00734 1/20 0.38
CNR1 P21554 1/20 0.38
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149170 1.00 HPGD (0.46) HPGDNPC1SMN1; SMN2RAB9ATSHR
SCHEMBL4151115 0.97 HPGD (0.49) HPGDNPC1SMN1; SMN2RAB9ATSHR
SCHEMBL4151117 0.97 HPGD (0.49) HPGDNPC1SMN1; SMN2RAB9ATSHR
SCHEMBL4004043 0.86 CNR1 (0.41) NPC1SMN1; SMN2RAB9ATP53MAPT
SCHEMBL5950786 0.86 CNR1 (0.41) NPC1SMN1; SMN2RAB9ATP53MAPT
SCHEMBL4003351 0.84 POLB (0.49) HPGDNPC1RAB9ATSHRTP53
SCHEMBL4003357 0.84 POLB (0.49) HPGDNPC1RAB9ATSHRTP53
SCHEMBL5950313 0.84 CNR1 (0.53) SMN1; SMN2MAPK1KMT2AALDH1A1CNR1
SCHEMBL5950778 0.83 NPC1 (0.42) HPGDNPC1SMN1; SMN2RAB9ATSHR
SCHEMBL5950775 0.83 NPC1 (0.42) HPGDNPC1SMN1; SMN2RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HPGD 51/4885NPC1 325/4885SMN1; SMN2 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.